search
Arrowhead Pharmaceuticals
Trends
- 1Arrowhead Pharma stock nears five-year high on Phase 3 success▼ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval
Arrowhead Pharmaceuticals shares are on track to reach their highest level in more than five years after positive Phase 3 trial results. Retail investors are celebrating the breakthrough, with hopes that the data will support a broader FDA approval for the company's pipeline beyond its initial indication, fueling a fresh rally in the stock.